Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
43.9 EUR | +1.74% | +1.85% | -21.99% |
25/04 | Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
18/03 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-21.99% | 821M | |
+20.69% | 47.02B | |
+49.51% | 41.86B | |
+0.04% | 41.76B | |
-4.27% | 28.8B | |
+11.85% | 26.05B | |
-21.66% | 19.15B | |
+3.91% | 12.55B | |
+28.08% | 12.34B | |
-4.61% | 11.82B |
- Stock Market
- Equities
- FYB Stock
- News Formycon AG
- EU Medicines Regulator Accepts Marketing Authorization Application for Formycon's Biosimilar Candidate